Suppr超能文献

新型冠状病毒病病毒学、疫苗、变异株和治疗方法的全面综述。

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.

机构信息

Department of Biomedical Sciences, West Virginia School of Osteopathic Medicine, 400 Lee Street North, Lewisburg, West Virginia, 24901, USA.

出版信息

Curr Med Sci. 2021 Dec;41(6):1037-1051. doi: 10.1007/s11596-021-2395-1. Epub 2021 Jul 9.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and 3.8 million deaths worldwide. Throughout the past year, multiple vaccines have already been developed and used, while some others are in the process of being developed. However, the emergence of new mutant strains of SARS-CoV-2 that have demonstrated immune-evading characteristics and an increase in infective capabilities leads to potential ineffectiveness of the vaccines against these variants. The purpose of this review article is to highlight the current understanding of the immunological mechanisms of the virus and vaccines, as well as to investigate some key variants and mutations of the virus driving the current pandemic and their impacts on current management guidelines. We also discussed new technologies being developed for the prevention, treatment, and detection of SARS-CoV-2. In this paper, we thoroughly reviewed and provided crucial information on SARS-CoV-2 virology, vaccines and drugs being used and developed for its prevention and treatment, as well as important variant strains. Our review paper will be beneficial to health care professionals and researchers so they can have a better understanding of the basic sciences, prevention, and clinical treatment of COVID-19 during the pandemic. This paper consists of the most updated information that has been available as of June 21, 2021.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是导致 2019 年冠状病毒病(COVID-19)的病原体,已在全球范围内导致超过 1.79 亿例感染和 380 万人死亡。在过去的一年中,已经开发并使用了多种疫苗,而其他一些疫苗仍在开发中。然而,SARS-CoV-2 的新突变株的出现表明其具有免疫逃避特性和感染能力增强,这导致疫苗对这些变体的潜在无效性。本文的目的是强调目前对病毒和疫苗的免疫机制的理解,并研究一些导致当前大流行的病毒的关键变体和突变及其对当前管理指南的影响。我们还讨论了为预防、治疗和检测 SARS-CoV-2 而开发的新技术。在本文中,我们全面回顾并提供了有关 SARS-CoV-2 病毒学、用于预防和治疗 COVID-19 的疫苗和药物以及重要的变异株的关键信息。我们的综述文章将有益于医疗保健专业人员和研究人员,使他们能够更好地了解大流行期间 COVID-19 的基础科学、预防和临床治疗。本文包含截至 2021 年 6 月 21 日的最新信息。

相似文献

1
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
Curr Med Sci. 2021 Dec;41(6):1037-1051. doi: 10.1007/s11596-021-2395-1. Epub 2021 Jul 9.
2
Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.
Cardiovasc Pathol. 2021 Jan-Feb;50:107278. doi: 10.1016/j.carpath.2020.107278. Epub 2020 Sep 2.
3
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
4
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.
Front Cell Infect Microbiol. 2020 Nov 25;10:587269. doi: 10.3389/fcimb.2020.587269. eCollection 2020.
5
Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
Mol Cell Biol. 2021 Aug 24;41(9):e0018521. doi: 10.1128/MCB.00185-21.
6
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
8
Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
Science. 2022 Mar 11;375(6585):1133-1139. doi: 10.1126/science.abn1900. Epub 2022 Mar 10.
9
Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists.
Am J Rhinol Allergy. 2021 Jan;35(1):122-131. doi: 10.1177/1945892420947929. Epub 2020 Aug 6.
10
COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Pharm Nanotechnol. 2020;8(4):323-353. doi: 10.2174/2211738508999200817163335.

引用本文的文献

1
2
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
Vaccines (Basel). 2025 May 22;13(6):548. doi: 10.3390/vaccines13060548.
3
Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application.
J Med Virol. 2025 Jun;97(6):e70447. doi: 10.1002/jmv.70447.
5
Mucosal implications of oral Jak3-targeted drugs in COVID patients.
Mol Med. 2025 May 23;31(1):203. doi: 10.1186/s10020-025-01260-z.
6
7
Patient Perspective on Dental Care Amidst COVID-19 Pandemic: A Survey During Omicron Stage.
J Patient Exp. 2025 May 9;12:23743735251342125. doi: 10.1177/23743735251342125. eCollection 2025.
8
Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.
Front Immunol. 2025 Feb 12;15:1376654. doi: 10.3389/fimmu.2024.1376654. eCollection 2024.

本文引用的文献

1
Nanoparticle-Based Strategies to Combat COVID-19.
ACS Appl Nano Mater. 2020 Aug 25;3(9):8557-8580. doi: 10.1021/acsanm.0c01978. eCollection 2020 Sep 25.
2
5
COVID-19 mRNA vaccines.
J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.
6
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
7
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
8
China's COVID vaccines are going global - but questions remain.
Nature. 2021 May;593(7858):178-179. doi: 10.1038/d41586-021-01146-0.
9
Access to and equitable distribution of COVID-19 vaccine in low-income countries.
NPJ Vaccines. 2021 Apr 14;6(1):54. doi: 10.1038/s41541-021-00323-6.
10
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell. 2021 May 27;184(11):2939-2954.e9. doi: 10.1016/j.cell.2021.03.055. Epub 2021 Mar 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验